ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Acuitive Technologies introduces Citregraft, a unique bone graft substitute designed to bind proteins and enhance regeneration

ALLENDALE, N.J., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Acuitive Technologies® commercializes Citregraft™, with its first use in a surgical case, performed on November 4th, 2025.

Bone graft substitutes are used to repair defects from trauma, infection, tumor removal, and reconstructive surgery. However, poor handling, low biological activity, variable resorption rate, and inadequate integration limit their effectiveness.

Leveraging the benefits of citrate in bone anatomy and physiology, Acuitive Technologies developed Citregen®, a citrate-based polymer technology that mimics natural bone chemistry and supplies the energy needed for regeneration. Exclusively made with Citregen and bioactive glass, Citregraft is a highly porous and bioactive synthetic bone graft substitute designed to interact with proteins to regenerate bony voids within the skeletal system.

250723 Citregraft High Res RenderCitregraft benefits include:

  •  Bioactive formulation to improve graft integration
  •  Easily morselized to fill and hold its position within irregular defects
  •  Absorbs 5 times its weight in fluids
  •  Synergizes with bone marrow aspirate (BMA) to bind proteins
  • Citrate increases cell energy for tissue regeneration

Citregraft was easily morselized to fill my tibial harvest site during BPTB ACL reconstruction. After soaking it in saline, it readily absorbed blood and growth factors from the harvest site and conformed perfectly to the defect,” said Robin Gehrmann, MD.

Citregraft overcomes the limitations of conventional bone graft substitutes by improving handling, liquid uptake, and protein binding. Its demonstrated bioactivity and ability to bind proteins establish Citregraft as a viable option for surgeons seeking innovative solutions for bone repair and regeneration.

Media Contact
Thomas McCarthy
Acuitive Technologies, Inc.
tmccarthy@acuitivetech.com
https://www.acuitivetech.com/

Data on file, TM251008, at Acuitive Technologies Inc., Allendale, NJ, USA

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/233ecf43-c685-4d77-ba95-b1a49b14eecb


Primary Logo

Recent Quotes

View More
Symbol Price Change (%)
AMZN  220.69
+3.55 (1.63%)
AAPL  271.49
+5.24 (1.97%)
AMD  203.78
-2.24 (-1.09%)
BAC  51.56
+0.56 (1.10%)
GOOG  299.65
+9.67 (3.33%)
META  594.25
+5.10 (0.87%)
MSFT  472.12
-6.31 (-1.32%)
NVDA  178.88
-1.76 (-0.97%)
ORCL  198.76
-11.93 (-5.66%)
TSLA  391.09
-4.14 (-1.05%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.